In vitro studies conducted on the BC cell line RT-4, which harbors the FGFR3-TACC3 translocation, demonstrated that pemigatinib markedly reduced FRS2 phosphorylation and activation of the MAPK signaling pathway. This evidence concerns the gene FGFR3 and breast cancer.